| GRSRX | JERSX | GRSRX / JERSX | |
| Total Expense Ratio | 1.34 | 1.16 | 116% |
| Annual Report Gross Expense Ratio | 1.34 | 1.16 | 116% |
| Fund Existence | 11 years | 18 years | - |
| Gain YTD | 2.924 | 3.763 | 78% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2500 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.05B | 312M | 656% |
| Annual Yield % from dividends | 2.89 | 2.90 | 100% |
| Returns for 1 year | 14.65 | 15.29 | 96% |
| Returns for 3 years | 18.88 | 14.27 | 132% |
| Returns for 5 years | 19.17 | 8.40 | 228% |
| Returns for 10 years | 56.18 | 73.85 | 76% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MMMSX | 23.99 | 0.33 | +1.39% |
| Victory Integrity Small/Mid-Cap Value Mb | |||
| GEMCX | 26.45 | 0.21 | +0.80% |
| Goldman Sachs Emerging Markets Eq C | |||
| ASIRX | 12.66 | 0.10 | +0.80% |
| Alger Small Cap Growth Institutional R | |||
| JDCRX | 43.37 | 0.18 | +0.42% |
| Janus Henderson Forty R | |||
| FTDZX | 175.43 | -2.44 | -1.37% |
| Franklin Biotechnology Discovery Adv | |||